Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Sho T, Suda G, Ogawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Ito J, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Terasita K, Takagi T, Kamiyama T, Taketomi A, Sakamoto N.
Sho T, et al. Among authors: kawagishi n.
Hepatol Res. 2020 Aug;50(8):966-977. doi: 10.1111/hepr.13511. Epub 2020 Jul 9.
Hepatol Res. 2020.
PMID: 32562334